Cedars-Sinai Discovery May Aid Doctors in Diagnosing At-risk Patients Before Symptoms Appear
A team led by a Cedars-Sinai physician-scientist has discovered a biomarker—a protein found in the blood—for the most common type of heart failure, a new study published today in JAMA Cardiology shows.
Heart failure with preserved ejection fraction (HFpEF) affects more than 6.5 million Americans each year. And now, thanks to the discovery of the first-ever biomarker for HFpEF, a simple blood test can reveal whether a patient’s heart is not making enough of an important protein. If the protein levels are decreased, the biomarker signal increases and physicians will be able to diagnose heart failure sooner, prescribe corrective medicines and prevent further disease progression.
“By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed,” said Robin Shaw, MD, PhD, the Wasserman Endowed Chair in Cardiology and professor of Medicine at the Smidt Heart Institute at Cedars-Sinai and principal investigator on the study. “Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed.”
Heart failure with preserved ejection fraction is a condition where the heart can contract, but has problems relaxing—limiting the heart’s ability to fill with blood between each beat—and therefore lowers the amount of blood moving forward with each contraction. Prior to the discovery of the biomarker, clinicians had to wait for patients to have symptoms to make a diagnosis of HFpEF and had to use an echocardiogram that measured how well the heart relaxed. There was no method to gauge the health of the heart muscle before symptoms developed or determine the severity of disease once symptoms were present.
The biomarker—named cBIN1 Score, or CS for short—allows doctors to measure muscle deterioration and measure a protein that regulates the heart’s ability to both contract and relax. As the protein decreases, CS increases, serving as an indication of onset heart failure. The CS biomarker can be measured using a simple blood draw.
This discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician. This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.
Eduardo Marbán, MD, PhD, director, Smidt Heart Institute
The CS biomarker is designed to be used in an outpatient clinic setting. For patients with known HFpEF, doctors can draw a CS level and use it to both guide current care, including medication adjustments, and predict the chances of a patient being admitted to the hospital in the next 12 months.
“More broadly, this discovery will allow the most at-risk patients—including older patients and patients with high blood pressure, diabetes or dyslipidemia—to be checked during an annual exam from their primary care physician,” said Eduardo Marbán, MD, PhD, director of the Smidt Heart Institute. “This pivotal research has the potential to impact millions of people and serve as a critical tool for preventive heart care.”
Symptoms of heart failure typically appear as fatigue, fluid weight gain, leg swelling and shortness of breath. Heart failure with preserved ejection fraction is typically diagnosed in elderly people or those living with high blood pressure, diabetes, elevated cholesterol, hypertension, obesity, obstructive sleep apnea, anemia, iron deficiency or diabetes. Its prevalence is projected to rise drastically over the coming decades. Previous studies have shown that women represent the majority of patients diagnosed with the disease.
As next steps, Cedars-Sinai researchers plan on identifying specialty populations in which the CS biomarker could be useful, including sex-based differences, those who have undergone a heart transplant or valve replacement, as well as individuals with no known heart disease or risk factors.
Learn more:Â Biomarker Discovered for Most Common Form of Heart Failure
The Latest on: Heart failure
[google_news title=”” keyword=”heart failure” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Heart failure
- New sensory device could cut heart failure hospitalisationson May 13, 2024 at 4:00 am
A study from Glasgow University has shown how new monitoring technology from Analog Devices could help prevent hospitalisations associated with heart failure.
- Yoga Can Help Heart Failure Patients Stay Strongon May 13, 2024 at 3:56 am
“Patients who practiced yoga on top of taking their medications felt better, were able to do more, and had stronger hearts than those who only took drugs for their heart failure,” lead researcher Dr.
- Heart Disease Risk In Women After Menopause: Cardiologist Recommends 8 Prevention Strategieson May 13, 2024 at 3:27 am
According to Dr. Borse, "After menopause, women face an increased risk of heart disease due to hormonal changes and other factors." Read on to know more about the lifestyle changes recommended by the ...
- Wearable device ‘may prevent heart failure hospitalisation’on May 13, 2024 at 3:07 am
Monitoring of heart failure patients in their homes using a wearable developed by Analog Devices Inc (ADI) has shown in a new study that it may be able to reduce costly hospitalisations.
- Cardurion’s PDE9 inhibitor increases cGMP in Phase IIa heart failure trialon May 13, 2024 at 2:41 am
Cardurion Pharmaceuticals has said its phosphodiesterase-9 (PDE9) inhibitor, CRD-740, has met the primary endpoint of its Phase IIa study in heart failure patients.
- Teen fitness may protect against later heart disease, study indicateson May 13, 2024 at 2:30 am
Disease linked to atherosclerosis is the leading cause of death ... points to the importance of cardiovascular exercise not only for heart health but also for muscle strength. The combination of the ...
- Study finds how yoga linked with symptom improvement in patients with heart failureon May 13, 2024 at 2:11 am
According to a study, yoga that focuses on breathing, meditation, and relaxation is connected to symptom improvement in people with heart failure.
- Heart failure patients who have taken Covid vaccine likely to live longer: Studyon May 13, 2024 at 1:14 am
Patients with heart failure who are vaccinated against Covid-19 are 82 per cent more likely to live longer than those who are not vaccinated, a new study said on Saturday.
- Heart failure patients who do yoga have stronger hearts and can be more activeon May 12, 2024 at 1:52 pm
Lisbon, Portugal – 12 May 2024: Yoga focused on breathing, meditation, and relaxation is linked with symptom improvement in patients with heart failure, according to research presented today at Heart ...
via Bing News